ORKA | tickerfilter.com

Fundamental analysis

17%

Profitability 0%

Dept financing 3%

Liquidity 50%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-4.63%

1 Month

-19.28%

3 Months

-14.13%

6 Months

-52.67%

1 Year

-52.67%

2 Year

-52.67%

Key data

Stock price

$10.09

P/E Ratio

N/A

DAY RANGE

$9.72 - $10.40

EPS

-$0.52

52 WEEK RANGE

$5.48 - $24.24

52 WEEK CHANGE

-$52.67

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

0.000

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-15-2025

BETA

0.29

PUBLIC FLOAT

N/A

AVERAGE 10 VOLUME

$225,279

AVERAGE 30 VOLUME

$409,717

Company detail

CEO: Lawrence Klein
Region: US
Website: ir.orukatx.com
Employees: 0
IPO year: 1997

Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/In Vitro, In Vivo Diagnostic Substances
Sector: Manufacturing

Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Our mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice per year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases.

ORKA - Oruka Therapeutics, Inc.